To know the effect of pushkarmooladi kwath in angina.

A study on role of pushkarmooladi Kwath as adjuvant therapy in vataja hridroga with Special reference to stable angina. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066273

Enrollment

Registered

2024-04-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I209- Angina pectoris, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex with age between 30-60years. 2.Patients having clinical presentation similar to Vataja Hridroga such as aayamyate , tudyate , nirmathyate, deeryate, sphotyate , paatyate, vepathu,veshtana, bheda , stambhaha, pramoha , shunyata, dravta, shosha. 3.Patients having symptoms at least 3 months or longer. 4.The patient must have a history of chest pain or discomfort that occurs with exertion or emotional stress and resolves with rest or medication. 5.Patient having diagnostic evidences of Stable Angina such as Exercise Stress Test, CPK-MB, Troponin T& I, SGOT, ST-T Changes , LBBB.

Exclusion criteria

Exclusion criteria: 1.Patients of either sex below 30 years & above 60 years 2.Patients giving history of recent chest pain with elevate troponin levels 3.Patients having any chronic systemic illness. 4.Alcoholics, drug abusers, pregnant and lactating women. 5.Patients who had a recent heart attack, MI ,severe valve disease. 6.Patients who have completed participation in any other clinical trial during past 6 months. 7.Any other condition which the Researcher/ Guide thinks may exclude the patient.

Design outcomes

Primary

Measure	Time frame
After intervention patient will get symptomatic relief in terms of severity and duration. Improvement in objective parameters i.e., ECG changes, LVEF, Exercise stress test findings , SGOT, CPK-MB, Lipid profile. Decreased disease progression in due course on follow-up after completion of trial. Improvement in Quality of life (WHO QOL BREF Criteria)Timepoint: 3 months duration of treatment and follow-up with every 1 month.	—

Measure

Time frame

After intervention patient will get symptomatic relief in terms of severity and duration. Improvement in objective parameters i.e., ECG changes, LVEF, Exercise stress test findings , SGOT, CPK-MB, Lipid profile. Decreased disease progression in due course on follow-up after completion of trial. Improvement in Quality of life (WHO QOL BREF Criteria)Timepoint: 3 months duration of treatment and follow-up with every 1 month.

—

Secondary

Measure	Time frame
Relief in severity and duration of the disease.Timepoint: 3 months study follow up at 1 month.	—

Countries

India

Contacts

Public ContactProf Rajendra Prasad

IMS BHU

dgautam@bhu.ac.in6392194981

Outcome results